• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations


The Biden administration today announced the first 10 prescription medications over whose prices it will negotiate for payment under Medicare Part D. The list includes several heavily advertised drugs for treating diabetes, heart failure, and other chronic diseases.

©alex mlx/stock.adobe.com
©alex mlx/stock.adobe.com

Authority for the Centers for Medicare and Medicaid Services (CMS) to conduct the first-ever price negotiations directly with pharmaceutical companies was included under the Inflation Reduction Act of 2022. Until then CMS had been prohibited from doing so.1

In a statement, CMS Administrator Chiquita Brooks-LaSure called the announcement “a significant and historic moment” for Medicare. “Our goal with these negotiations is to improve access to some of the costliest drugs for millions of people with Medicare while driving competitions and innovation,” LaSure said.2

“Thanks to the landmark Inflation Reduction Act, we are closer to reaching President Biden’s goal of increasing availability and lowering prescription drug costs for all Americans,” Xavier Becerra, secretary of the US Department of Health and Human Services (HHS) said in an HHS statement.1

The drugs whose prices the government wants to negotiate and their uses include:

  • Apixaban (Eliquis): Indicated for prevention and treatment of blood clots.
  • Empagliflozin (Jardiance): Indicated for type 2 diabetes and heart failure.
  • Rivaroxaban (Xarelto): Indicated for prevention and treatment of blood clots; reducing risk for patients with CAD/PAD.
  • Sitagliptin (Januvia): Indicated for type 2 diabetes.
  • Dapagliflozin (Farxiga): Indicated for type 2 diabetes, heart failure, and chronic kidney disease.
  • Sacubitril/valsartan (Entresto): Indicated for heart failure.
  • Etanercept (Enbrel): Indicated for rheumatoid arthritis, psoriasis, and psoriatic arthritis.
  • Ibrutinib (Imbruvica): Indicated for blood cancers.
  • Ustekinumab (Stelara): Indicated for psoriasis, psoriatic arthritis, Crohns disease, and ulcerative colitis.
  • Insulin aspart (Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill): Indicated for use in diabetes mellitus.

According to HHS, the drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs between June 1, 2022 and May 3, 2023, the time period used to determine which drugs were eligible for negotiation. Part D enrollees taking these drugs paid $3.4 billion in out-of-pocket expenses for them in 2022.1

The Congressional Budget Office has estimated that negotiating prices for them will save Medicare close to $100 billion over a decade.

Pharmaceutical manufacturers with a drug included in the list have until October 1 to decide whether to participate in the negotiations. Those that don’t will either have to pay an excise tax or no longer have their products included in Medicare and Medicaid. Negotiations will continue until August 1, 2024, after which CMS will announce the “maximum fair price” agreed upon for each drug. The prices will take effect at the start of 2026.2

Three organizations—the National Infusion Center Association, the Global Colon Cancer Association and Pharmaceutical Research and Manufacturers of America, have sued in federal court to try and stop the negotiations.

If the negotiating program is allowed to continue, CMS will select 15 additional drugs covered under Medicare Part D for 2027, 15 covered under both Parts B and D for 2028, and 20 drugs for each year after that.1


1. HHS selects the first drugs for Medicare durg price negotiation. News release. HHS.gov. August 29, 2023. Accessed August 29, 2023. https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html
2. Statements by CMS leadership on historic announcement of first selected drugs for medicare price negotiation. Press release. CMS.gov. August 29, 2023. Accessed August 29, 2023. https://www.cms.gov/newsroom/press-releases/statements-cms-leadership-historic-announcement-first-selected-drugs-medicare-drug-price-negotiation

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.